N-Boc-D-2-OCF3-phenylalanine | 959845-31-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Boc-D-2-OCF3-phenylalanine
• 英文别名: N-Boc-D-2-trifluoromethoxy phenylalanine；(R)-2-tert-butoxycarbonylamino-3-(2-trfluoromethoxy-phenyl)-propionic acid；(R)-2-Tert-butoxycarbonylamino-3-(2-trifluoromethoxy-phenyl)-propionic acid；(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[2-(trifluoromethoxy)phenyl]propanoic acid
• CAS: 959845-31-9
• 化学式: C₁₅H₁₈F₃NO₅
• 分子量: 349.307
• InChiKey: XXUYHGNJHWOXLL-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-Boc-D-2-OCF3-phenylalanine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 pyrazine-2-carboxylic acid [(R)-1-((R)-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-ylcarbamoyl)-2-(2-trifluoromethoxy-phenyl)-ethyl]-amide
  参考文献：
  名称：

  WO2007/145922

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(三氟甲氧基)苄基溴 在 lithium hydroxide 、 正丁基锂 、 水 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 乙腈 为溶剂， 反应 21.75h， 生成 N-Boc-D-2-OCF3-phenylalanine
  参考文献：
  名称：

  WO2007/145922

  摘要：

  公开号：

文献信息

• Benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain
  作者：Scott B. Hoyt、Clare London、Hyun Ok、Edward Gonzalez、Joseph L. Duffy、Catherine Abbadie、Brian Dean、John P. Felix、Maria L. Garcia、Nina Jochnowitz、Bindhu V. Karanam、Xiaohua Li、Kathryn A. Lyons、Erin McGowan、D. Euan MacIntyre、William J. Martin、Birgit T. Priest、McHardy M. Smith、Richard Tschirret-Guth、Vivien A. Warren、Brande S. Williams、Gregory J. Kaczorowski、William H. Parsons

  DOI：10.1016/j.bmcl.2007.09.032

  日期：2007.11

  A series of benzazepinones were synthesized and evaluated as hNa(v)1.7 sodium channel blockers. Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain.

  合成了一系列苯并ze庚酮，并将其评估为hNa（v）1.7钠通道阻滞剂。该系列中的几种化合物具有良好的口服生物利用度和暴露能力，并且在神经性疼痛的大鼠模型中有效。
• Benzaepinones as sodium channel blockers
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07888345B2

  公开（公告）日：2011-02-15

  Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.

  公式（I）所代表的苯并氮烷酮化合物，或其药学上可接受的盐。制药组合物包括有效量的本化合物，单独或与一种或多种其他治疗活性化合物结合，并含有药学上可接受的载体。治疗与钠通道活性相关或由其引起的病症的方法，包括例如急性疼痛、慢性疼痛、内脏疼痛、炎症性疼痛、神经病理性疼痛、癫痫、肠易激综合征、尿失禁、瘙痒、过敏性皮炎、抑郁症、焦虑症、多发性硬化症和躁郁症，包括单独或与一种或多种其他治疗活性化合物结合的本化合物的有效量的给药。给予局部麻醉的方法包括给予本发明化合物的有效量，单独或与一种或多种其他治疗活性化合物结合，并含有药学上可接受的载体。
• ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS
  申请人：Inoue Tadashi

  公开号：US20120101105A1

  公开（公告）日：2012-04-26

  The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Na v1.3 and Na v1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.

  本发明涉及公式(I)或其药学上可接受的盐的芳基取代羧酰胺衍生物，其具有T型钙通道或电压门控钠通道的阻滞活性，如Nav1.3和Nav1.7等Tetrodotoxin敏感(TTX-S)阻滞剂，并且在涉及T型钙通道或电压门控钠通道的疾病或疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及在涉及T型钙通道或电压门控钠通道的疾病或疾病的预防或治疗中使用这些化合物和组合物的用途。
• Benzaepinones as Sodium Channel Blockers
  申请人：Hoyt Scott B.

  公开号：US20090181946A1

  公开（公告）日：2009-07-16

  Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.

  公式（I）所代表的苯并氮杂环酮化合物，或其药学上可接受的盐。制药组合物包括有效量的本化合物，单独使用或与一个或多个其他治疗活性化合物结合，并且药学上可接受的载体。治疗与钠通道活性相关或由其引起的疾病的方法，包括例如急性疼痛，慢性疼痛，内脏疼痛，炎性疼痛，神经病理性疼痛，癫痫，肠易激综合征，尿失禁，瘙痒，过敏性皮炎，抑郁症，焦虑症，多发性硬化症和躁郁症，包括单独使用或与一个或多个其他治疗活性化合物结合的本化合物的有效量的给药。一种局部麻醉的给药方法包括给予本发明化合物的有效量，单独使用或与一个或多个其他治疗活性化合物结合，并且药学上可接受的载体。
• A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain
  作者：Scott B. Hoyt、Clare London、Catherine Abbadie、John P. Felix、Maria L. Garcia、Nina Jochnowitz、Bindhu V. Karanam、Xiaohua Li、Kathryn A. Lyons、Erin McGowan、Birgit T. Priest、McHardy M. Smith、Vivien A. Warren、Brande S. Thomas-Fowlkes、Gregory J. Kaczorowski、Joseph L. Duffy

  DOI：10.1016/j.bmcl.2013.03.121

  日期：2013.6

  A series of benzazepinones were synthesized and evaluated for block of Na(v)1.7 sodium channels. Compound 30 from this series displayed potent channel block, good selectivity versus other targets, and dose-dependent oral efficacy in a rat model of neuropathic pain. (C) 2013 Elsevier Ltd. All rights reserved.